British Columbia-based Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) recently entered a definitive agreement to provide its patented DehydraTECH(TM) technology to Cannadips CBD. An article discussing the company reads, “The agreement announced recently provides Cannadips CBD with exclusive access rights to Lexaria’s technology for the U.S. market for 10 years, granting the ‘Original Smokeless CBD Dip … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Strikes Licensing Deal with Cannadips CBD”
Lexaria’s DehydraTECH(TM) drug delivery platform a feasible and healthier alternative to other delivery methods The fast-acting, high absorption technology improves dipping experience and consumer satisfaction Company expects to more than double its 2019 revenue this year, will pursue a new capital markets strategy to qualify for listing on a nationally recognized U.S. exchange Lexaria Bioscience … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Demonstrates Applicability of Drug Delivery Platform Through Relationships with Fortune 500 Leaders”
Lexaria’s fast-acting, high absorption technology will improve dipping experience and consumer satisfaction Partnership will enable Lexaria’s to provide its DehydraTECH(TM) drug delivery platform to Cannadips Cannnabis products in California and nationwide Cannadips to open one-of-a-kind cannabis oral pouch and dip research facility Global innovators in drug delivery platforms Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters Cannabis Oral Pouch & Dip Niche through Lucrative New Partnership”
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced that its DehydraTECH(TM)-enabled CBD infused powders are now available for sale across the U.S. to businesses wanting to produce topicals and edibles with clinically proven performance for increased consumer satisfaction and improved stability. Consumers of both CBD/hemp and cannabis have … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH(TM)-Enabled CBD Infused Powders Available for Sale Across the US”
British Columbia-based, biodelivery technology developer Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is committed to the idea that better alternative methods for drug delivery exist than inhalation. A recent article discussing the company reads, “Swallowed medications have historically been slower to provide effective action than inhaled ones, leading substance users looking for a quick fix to … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Providing Alternative to Inhalation via Patented Oral Drug-Delivery Technology”
Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) 2.0 version of its patented DehydraTECH(TM) oral drug-delivery technology has demonstrated its power to deliver more cannabidiol (“CBD”) into the bloodstream than generic industry-control formulations (http://nnw.fm/SR9dw). An article discussing the company reads, “The company’s 2.0 technology is specifically being developed for effectiveness in helping to deliver its drug payload across … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Technology Accelerates Delivery of CBD into Bloodstream”
Lexaria Bioscience is a company dedicated to developing effective oral ingestion methods for drug substances that rival the rapid-delivery qualities of more health-dangerous inhaled-drug products. Inhalation is a particularly popular method of using tobacco and cannabis products, despite government warnings about the scientifically established dangers of doing so Lexaria has been boosting its profile and … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Inks Licensing Deal with Smokeless Cannadips CBD Product Maker”
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced that it has reached a new definitive agreement to provide its patented DehydraTECH(TM) technology to Cannadips’ cannabis products, both in its current California market and across the United States. According to the update, Lexaria’s DehydraTECH fast-acting, high-absorption technology is perfectly … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) to Provide Patented DehydraTECH(TM) to Cannadips’ Cannabis Products in California and Across the US”
Growing interest in the company’s innovative DehydraTECH™ drug delivery platform from large global corporations Lexaria’s strategy to be listed on a nationally recognized U.S. exchange will help the company access a significantly larger audience of investors Lexaria has 16 patents with another 60 pending worldwide and is the only company to hold a patent for … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Expects Sustainable Revenue Growth, Plans New Capital Markets Strategy in 2020”
Lexaria Bioscience continues to advance the effectiveness of its proprietary DehydraTECH technology, a formulation that teams with drug substances such as nicotine and cannabidiol to quickly carry those drugs into a user’s blood stream Recent concerns about the safety of vape products and ongoing concerns about the safety of tobacco are opening doors to Lexaria’s … Continue reading “Concerns About Vape Addiction, Injury Provide Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) with Opportunity”
